Necrotizing Autoimmune Myositis Market

Necrotizing autoimmune myositis is also known as Immune-Mediated Necrotizing Myopathy (IMNM), is an extremely rare autoimmune muscle disease resulting in symptoms such as skeletal muscle inflammation, pain, and weakness leads to difficulty in muscle movement.

The histopathologically of necrotizing autoimmune myositis is myocyte necrosis and regeneration without significant inflammation. The most commonly affected muscles include the muscles closer to the body such as the upper arms, hips, shoulders, thighs, and neck.

Necrotizing autoimmune myositis currently has no cure and the treatment is symptomatic. The exact cause of necrotizing autoimmune myositis is unknown although certain medications such as statins, certain autoantibodies, and diseases such as cancer, viral infections, and others are associated with it.

The rising screening rates, awareness coupled with the growing use of drugs such as statins, certain autoantibodies, and incidence of diseases such as cancer, viral infections, and others is the prime driver of the necrotizing autoimmune myositis market.

The estimated prevalence of necrotizing autoimmune myositis in the U.S. is approximately 300 cases. Myositis has an incidence of 5 to 10 people per 1,000,000 of a population across all age groups above 18 years old.

The attractive reimbursement and financial incentives afforded to rare diseases affecting fewer than 200,000 people is a prime driver of the market. The 'orphan' status allows the drug developer incentives until the marketing approval to all stages of the drug development such as tax credits on clinical research, elaboration of an application file necessary for marketing approval, technical assistance during the application and simplification of administrative procedures such as fast approval resulting in reduction of the waiting period and the amount of registration fees.

The growing valuation of orphan drug designation by investors is driving a large research and development expenditure. It has been witnessed that on average, the stock price of a pharmaceutical company rises by 3 to 4 % after the orphan drug designation is awarded resulting in increasing the valuation of the company. It also places the company at the apex of the technological chain resulting in substantial growth in public and investor goodwill.

The growing geriatric population is another driver of the necrotizing autoimmune myositis as the age of onset ranges from 30 to 70 years. The growing R&D intensively and attractive government support and initiatives are other drivers of the growth of the necrotizing autoimmune myositis market.

Strong government support and incentives to biotech and pharmaceutical sectors are another driver of the growth of the market. For example, the Government of India and China have made the biotech sector a strategic one owing to its positive externalities on other sectors and rich foreign exchange earning potential.

For example, in India, the Department of Biotechnology (DBT) along with other government-funded institutions such as the National Biotechnology Board (NBTB) are collaborating to project India as a global hub for biotech research. The Indian Union Budget 2017-18, allocated US$ 333.31 million aimed at implementing the national biotech strategy with a target to increase the turnover of the biotech sector to $100 billion by 2025 from approximately $7 billion in 2016.

However, the constraints such as high cost of treatment, and lack of curative treatment is hampering the Necrotizing Autoimmune Myositis market.

Based on regions, the global necrotizing autoimmune myositis market is classified into North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East & Africa, and Asia Pacific market excluding Japan. North America led by the U.S. is expected to dominate the global necrotizing autoimmune myositis market owing to excellent healthcare infrastructure, large screening rates, and attractive reimbursement rates.

The Europe necrotizing autoimmune myositis market is expected to be led by the Germany, France, Italy, Spain, Portugal and the UK. The Latin America and the Middle East and Africa necrotizing autoimmune myositis market is constrained due to the low healthcare expenditure and poor economic conditions.

The Middle East and Africa necrotizing autoimmune myositis market are projected to be dominated by the Gulf economies of UAE, Saudi Arabia, and Kuwait owing to their large wealth relative to the African nations.

The Asia Pacific market is expected to expand at a furious pace owing to growing research and development expenditure and the support of the governments to the technology sector. The growing economy of China and India is expected to drive large market adoption.

Some of the major players in the global Necrotizing Autoimmune Myositis market are GlaxoSmithKline plc, Dr. Reddy's Laboratories, Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.), Hetero Drugs Limited, AbbVie Inc., Teva Pharmaceutical Industries, Novartis AG, and others.

The necrotizing autoimmune myositis report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain 

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint.